Press release
Pancreatic Ductal Adenocarcinoma (PDAC) Market Detailed Industry Report Analysis 2025-2034
Pancreatic Ductal Adenocarcinoma (PDAC) Market
Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer, accounting for over 90% of all cases. It is one of the deadliest cancers worldwide, characterized by late diagnosis, aggressive progression, and limited survival rates. Despite advances in oncology, PDAC remains a significant challenge due to its resistance to conventional therapies and high recurrence rates.
The global healthcare industry is now focusing intensively on PDAC through precision medicine, immunotherapy, targeted biologics, and advanced diagnostics. Improved patient stratification, biomarker-driven treatments, and ongoing clinical trials are reshaping the market outlook.
In 2024, the global PDAC market is valued at USD 4.5 billion. By 2034, it is projected to reach USD 10.1 billion, expanding at a CAGR of 8.3%. This growth reflects both the rising prevalence of pancreatic cancer and the acceleration of drug innovation in oncology.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/71554
Market Overview
• Market Size (2024): USD 4.5 billion
• Forecast (2034): USD 10.1 billion
• CAGR (2024-2034): 8.3%
• Key Growth Drivers:
o Rising global incidence of pancreatic cancer.
o Expansion of biomarker-driven and precision oncology.
o Strong pipeline of immunotherapies and targeted agents.
o Growing investments in oncology clinical trials.
• Key Challenges:
o High mortality and poor prognosis; 5-year survival remains less than 10%.
o Therapy resistance and limited efficacy of chemotherapy.
o High treatment costs and limited access in emerging markets.
• Leading Players: Roche, Novartis, Bristol Myers Squibb, Pfizer, AstraZeneca, Eli Lilly, Merck & Co., Amgen, Ipsen, and Guardant Health.
Segmentation Analysis
By Therapy Type
• Chemotherapy (gemcitabine, FOLFIRINOX regimens)
• Targeted Therapies (PARP inhibitors, KRAS inhibitors, EGFR inhibitors)
• Immunotherapy (checkpoint inhibitors, cancer vaccines, CAR-T therapies in trials)
• Radiation Therapy & Combination Approaches
• Supportive & Palliative Care
By Biomarker Status
• KRAS Mutant PDAC
• BRCA1/2 Mutated PDAC
• Microsatellite Instability-High (MSI-H) / dMMR PDAC
• Other Molecular Subtypes
By Stage of Disease
• Resectable
• Locally Advanced (Unresectable)
• Metastatic
By End User
• Hospitals & Oncology Centers
• Research & Academic Institutes
• Clinical Trial Facilities
• Specialty Cancer Clinics
By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa
Segmentation Summary:
Chemotherapy remains the backbone of treatment, but the fastest-growing segments are targeted therapies and immunotherapies, which are showing promising survival benefits in biomarker-selected patients. Metastatic PDAC accounts for the majority of treatment demand, reflecting late-stage diagnoses.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/71554/pancreatic-ductal-adenocarcinoma-market
Regional Analysis
North America
• Largest market due to high incidence, advanced oncology infrastructure, and rapid adoption of innovative therapies.
• U.S. leads with strong biomarker testing and clinical trial enrollment.
Europe
• Significant market, with Germany, France, and the UK leading clinical research efforts.
• Strong emphasis on access to precision medicine and oncology drug reimbursement.
Asia-Pacific (APAC)
• Fastest-growing region due to rising prevalence in China, Japan, and India.
• Expanding healthcare infrastructure and government-backed oncology programs.
Latin America
• Brazil and Mexico dominate, but access to advanced therapies remains limited.
• Reliance on chemotherapy is higher due to affordability challenges.
Middle East & Africa (MEA)
• GCC nations investing in oncology centers and advanced diagnostics.
• Africa faces significant barriers in early detection and treatment.
Regional Summary:
While North America and Europe dominate revenues, Asia-Pacific is projected to record the fastest CAGR (~9.6%), fueled by rising prevalence and growing healthcare investments in precision oncology.
Market Dynamics
Key Growth Drivers
• Rising Disease Burden: Pancreatic cancer ranks among the top five causes of cancer-related mortality worldwide.
• Precision Medicine Expansion: Biomarker testing enabling targeted drug use (e.g., BRCA, KRAS).
• Strong R&D Pipeline: Multiple clinical trials for immunotherapies and novel agents.
• Technological Advances: Liquid biopsies and AI-driven diagnostics improving early detection.
Key Challenges
• Poor Prognosis: Late diagnosis limits resection and therapy options.
• Resistance Mechanisms: Tumor microenvironment creates barriers for drug delivery.
• Cost Barriers: Targeted therapies and immunotherapies remain expensive.
Latest Trends
• KRAS Inhibitors: A breakthrough focus area in PDAC clinical trials.
• Immunotherapy Combinations: Checkpoint inhibitors combined with chemotherapy or radiation.
• Cancer Vaccines: Therapeutic vaccines being developed to induce durable immune responses.
• Liquid Biopsy Adoption: Non-invasive detection of mutations for patient stratification.
Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71554
Competitor Analysis
Key Companies in PDAC Market:
• Roche - Oncology leader with biomarker-driven therapies.
• Novartis - Expanding KRAS and immunotherapy pipelines.
• Bristol Myers Squibb - Checkpoint inhibitors for solid tumors.
• Pfizer - Combination oncology regimens in PDAC.
• AstraZeneca - PARP inhibitors for BRCA-mutated PDAC.
• Eli Lilly - Gemcitabine-based therapies and novel agents in trials.
• Merck & Co. - Keytruda (pembrolizumab) applications in MSI-H/dMMR PDAC.
• Amgen - KRAS inhibitors for advanced pancreatic cancer.
• Ipsen - Onivyde (liposomal irinotecan) for metastatic PDAC.
• Guardant Health & Foundation Medicine - Liquid biopsy and precision diagnostics.
Competitive Summary:
The PDAC market is highly competitive, with big pharma focusing on immuno-oncology and targeted drugs. While chemotherapy remains standard, companies are racing to gain first-mover advantage in KRAS-targeted therapies and immunotherapy combinations, which are expected to redefine treatment paradigms by 2030.
Conclusion
The Pancreatic Ductal Adenocarcinoma (PDAC) Market is entering a new era, with precision medicine and advanced therapies reshaping the treatment landscape. By 2034, the market will more than double, reaching USD 10.1 billion, driven by biomarker-driven drug adoption and innovative oncology pipelines.
Key Takeaways:
• Market size: USD 4.5B (2024) → USD 10.1B (2034).
• CAGR: 8.3%.
• Chemotherapy dominates today, but targeted and immunotherapies are fastest-growing.
• North America leads, while Asia-Pacific grows fastest at 9.6% CAGR.
• Innovation in KRAS inhibitors, immunotherapy, and diagnostics will define the next decade.
This report is also available in the following languages : Japanese (膵管腺癌市場), Korean (췌장관 선암 시장), Chinese (胰腺导管腺癌市场), French (Marché de l'adénocarcinome canalaire pancréatique), German (Markt für duktales Pankreasadenokarzinom), and Italian (Mercato dell'adenocarcinoma duttale pancreatico), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71554
Our More Reports:
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
IRFAN TAMBOLI
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pancreatic Ductal Adenocarcinoma (PDAC) Market Detailed Industry Report Analysis 2025-2034 here
News-ID: 4170358 • Views: …
More Releases from Exactitude Consultancy
Cell Therapy Manufacturing Market to Reach USD 28.4 Billion by 2034, Growing at …
Introduction
Cell therapy has emerged as a transformative pillar of modern medicine, offering the potential to repair, replace, or regenerate damaged tissues and organs. From CAR-T cell therapies for oncology to stem cell therapies for regenerative medicine, the field is redefining treatment paradigms across oncology, neurology, cardiology, and rare diseases.
As clinical pipelines expand and more therapies achieve regulatory approval, demand for efficient and scalable cell therapy manufacturing has surged. Specialized technologies…
Despite safety concerns, adavosertib exhibits early antitumor activity in uterin …
Uterine serous carcinoma (USC) is a rare but highly aggressive subtype of endometrial cancer, accounting for less than 10% of endometrial cancer cases but contributing to a disproportionately high mortality rate. It is often diagnosed at advanced stages, making it difficult to treat with conventional methods.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72873
In recent years, the treatment landscape has expanded beyond chemotherapy and surgery to include targeted therapies,…
Market for Catheter-Related Bloodstream Infections: Overview, Therapies, and Imp …
Catheter-related bloodstream infections (CRBSIs) are among the most common and serious complications associated with intravascular catheters used in hospitals and long-term care settings. These infections can lead to prolonged hospital stays, increased healthcare costs, and higher mortality rates. With the rising use of central venous catheters, particularly among critically ill patients, oncology cases, and those requiring long-term intravenous therapy, the global demand for effective prevention and treatment solutions is growing…
ADC Technology Market to Reach USD 33.7 Billion by 2034, Growing at 13.2% CAGR
Introduction
Antibody-drug conjugates (ADCs) represent one of the most innovative breakthroughs in oncology, combining the target specificity of monoclonal antibodies with the cytotoxic potency of chemotherapeutic agents. By delivering highly toxic payloads directly to cancer cells, ADCs minimize systemic toxicity and enhance therapeutic efficacy.
As cancer incidence rises worldwide and the limitations of conventional chemotherapy become more evident, ADC technology is gaining momentum. With advancements in linker chemistry, payload design, and next-generation…
More Releases for PDAC
Pancreatic Ductal Adenocarcinoma Pipeline 2025: Pioneering Clinical Developments …
Key companies in pancreatic ductal adenocarcinoma market include Cardiff Oncology, XOMA, Alphamab, Cantargia, RenovoRx, Syntrix Biosystems, Eucure Biopharma, Panbela Therapeutics, Jeil Pharmaceutical, Elicio Therapeutics, Cend Therapeutics, Incyte Corporation, I-Mab Biopharma, Medicenna Therapeutics, and Tarveda Therapeutics.
With Pancreatic Ductal Adenocarcinoma (PDAC) reaching epidemic levels globally and contributing to comorbidities such as diabetes, cardiovascular disease, and other cancers, there is an increasing demand for safer and more effective therapies. According to DelveInsight, the…
The Oregon Group to Attend PDAC 2025 in Toronto
LONDON, February 20, 2025 - The Oregon Group is pleased to announce its participation in the annual PDAC Convention in Toronto, taking place from March 2-5, 2025.
Chairman Anthony Milewski and Christian Purefoy will engage in a series of meetings and interviews throughout the event.
"PDAC is always a highlight of the year, and 2025 is set to be especially significant given shifting global dynamics and the rising importance of critical minerals.…
Pancreatic Ductal Adenocarcinoma (PDAC) Pipeline Analysis (2023) Covering Clinic …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 80+ key pharma and biotech companies are working on 80+ pipeline drugs in the Pancreatic Ductal Adenocarcinoma therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Pancreatic Ductal Adenocarcinoma Pipeline Insight,…
Pancreatic Ductal Adenocarcinoma (PDAC) Pipeline Analysis (2023) Covering Clinic …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 80+ key pharma and biotech companies are working on 80+ pipeline drugs in the Pancreatic Ductal Adenocarcinoma therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Pancreatic Ductal Adenocarcinoma Pipeline Insight,…
Pancreatic Ductal Adenocarcinoma (PDAC) Market to Witness Upsurge in Growth Duri …
As per DelveInsight, the Pancreatic Ductal Adenocarcinoma Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of Pancreatic Ductal Adenocarcinoma and the launch of new therapies in the market.
DelveInsight's "Pancreatic Ductal Adenocarcinoma (PDAC) Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Pancreatic Ductal Adenocarcinoma…
EuroGeoSurveys at the PDAC 2021 Virtual Convention
The Prospectors & Developers Association of Canada (PDAC) has wrapped up its first-ever virtual convention that happened between March 8-11, 2021, receiving positive feedback and industry accolades. The annual PDAC Convention is the premier event of the world’s mineral exploration and mining industry that brings together mining executives, geologists, government officials, investors, analysts, and students from around the globe. With over 7,200 members around the world, PDAC’s mission is to…
